Coherus Oncology (CHRS) Free Cash Flow (2013 - 2026)

Coherus Oncology has disclosed Free Cash Flow across 14 years of filings, most recently posting -$57.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$57.9 million, down 89.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $304.5 million (up 750.87% YoY), and the FY2025 annual result was $331.8 million, up 59.99% from the prior year.
• Free Cash Flow came in at -$57.9 million for Q1 2026 at Coherus Oncology, down from -$28.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $436.8 million in Q2 2025 to a low of -$100.0 million in Q4 2022.
• The 5-year median for Free Cash Flow is -$39.0 million (2023), against an average of $3.7 million.
• Across the five-year window, Free Cash Flow slumped 8343.95% in 2022 and surged 355.63% in 2024, its largest moves.
• Coherus Oncology's Free Cash Flow stood at -$100.0 million in 2022, then soared by 87.03% to -$13.0 million in 2023, then soared by 320.55% to $28.6 million in 2024, then slumped by 198.2% to -$28.1 million in 2025, then plunged by 106.06% to -$57.9 million in 2026.
• The last three Free Cash Flow figures came in at -$57.9 million (Q1 2026), -$28.1 million (Q4 2025), and -$46.3 million (Q3 2025), per Business Quant data.